Effect of puerarin administration on serum NOD-like receptor protein 3 (NLRP3) inflammasome, C1Q/TNF-related protein 3 (CTRP3) and lipoprotein-associated phospholipase 2 (LP-PLA2) levels.

Abstract

Background: Coronary heart disease (CHD) is a cardiovascular disease with a high incidence in elderly patients. This article aimed to evaluate the clinical efficacy of puerarin (Pue) as an adjuvant therapy in elderly patients with CHD and the effects of Pue on serum NOD-like receptor protein 3 (NLRP3) inflammasome, C1q/TNF-Related Protein 3 (CTRP3) and lipoprotein-associated phospholipase 2 (Lp-PLA2) levels.

Methods: This retrospective cohort study compared two treatment approaches for CHD patients at Beijing University of Chinese Medicine Third Affiliated Hospital. Fifty-nine patients received standard treatment (5% glucose + nitroglycerin), and 59 received a new treatment (5% glucose + Pue injection). Outcomes were assessed using electrocardiograms, laboratory tests, and cardiac function evaluations.

Results: Relative to the controls, the study subjects had a reduction in the number of angina episodes and an increase in exercise tolerance. In addition, the serum NLRP3 inflammasome and Lp-PLA2 distinctly decreased, and the serum CTRP3 distinctly increased in study subjects.

Conclusions: The administration of puerarin as an adjuvant therapy in elderly patients with coronary heart disease demonstrated significant clinical efficacy, as evidenced by reduced angina episodes and improved exercise tolerance; this might be driven through inflammatory and lipid metabolism pathways.